Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition
Administration of a small molecule PIM-2 inhibitor in combination with the epigenetic drug azacitidine is one of the effective ways to treat MDS. Our study lays a foundation for future clinical trials in patients with MDS.
Authors
- Yixuan Guo (ORCID: https://orcid.org/0000-0002-7967-5873)
- Zhaoyun Liu
- Kai Ding
- Wenhui Lei
- Xiaohan Liu
- Chun Yang
- Rong Fu
Institutions
- Tianjin Normal University (CN)
- Tianjin Chengjian University (CN)
- Tianjin Medical University General Hospital (CN)
- Tianjin People's Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1186/s12885-025-14657-0
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00